Buy & Sell Global X Robotics and Artificial Intelligence ETF (BOTZ) – Global X Robotics and Artificial Intelligence ETF Price Today
Aura AI Summary
Key Stats
- -Market Cap
- -Sector
- -16.23%3M Drawdown
- -Enterprise Value
- -Dividend Yield
- 96% Buy | 4% SellTrading Activity
- 84 daysTypical Hold Time
Over the past 52 weeks, Global X Robotics and Artificial Intelligence ETF has traded between a low of $30.45 and a high of $41.63, highlighting its annual price range. Over the past three months, Global X Robotics and Artificial Intelligence ETF has recorded a drawdown of -16.23%, reflecting recent price volatility. On average, investors hold Global X Robotics and Artificial Intelligence ETF for approximately 84 days, indicating typical investor behavior on the platform.
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Most Recent News
Emerson Electric partners with Aramco to develop advanced corrosion monitoring systems.
Emerson Electric announced a collaboration with Saudi Aramco to co-develop next-generation corrosion management solutions using ultrasonic online monitoring and wireless technology. This partnership aims to improve operational safety and performance ...

Modern inflation differs from the 1970s, driven by supply issues, not wage-price spirals.
Current inflation trends in the U.S. are often compared to the 1970s stagflation, but experts highlight key differences. Unlike the 1970s, today's inflation is driven mainly by supply-side pressures such as rising commodity prices and geopolitical te...

Atea Pharma shows low drug interaction risk for new Hepatitis C treatment and promising Hepatitis E antiviral data.
Atea Pharmaceuticals announced Phase 1 results indicating their Hepatitis C treatment regimen, combining bemnifosbuvir and ruzasvir, has a low risk of drug-drug interactions with common medications like omeprazole and rosuvastatin. This supports easi...
